Relay Therapeutics Inc (RLAY) Stock Analysis
Verdict: WATCH (do not buy)
Clinical milestone momentum in PI3Ka/FGFR2 is offset by $235M annual cash burn and relentless insider selling near 52-week highs.
Investment score: 43/100
Analysis as of
Is Relay Therapeutics Inc stock worth reviewing? The TradeMates thesis
Positive clinical pipeline advancement is balanced by persistent operating losses (-$302.74M in 2025) and heavy insider selling.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Relay Therapeutics Inc opportunities and risks
What speaks for RLAY
- RLY-2608 mutant-selective PI3Ka pipeline validation
What speaks against RLAY
- Relentless cash burn rate ($235.87M annually) and commercial gap
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RLAY | n/a | 376.3x | n/a | -566.6% | -2763.6% | -5.4% |
| TNGX | n/a | 73.8x | n/a | 98.2% | -229.9% | -3.6% |
| PBLS | n/a | 25951.4x | n/a | 100.0% | -66066.9% | -1.4% |
| VKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -10.5% |
| CELC | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.9% |
| VCYT | 31.8x | 6.5x | 26.1x | 72.1% | 20.4% | 4.5% |
| Peer median | n/a | 6.5x | n/a | 72.1% | 0.0% | -3.6% |
Frequently asked questions about Relay Therapeutics Inc (RLAY)
Is RLAY stock a good investment?
The TradeMates model rates Relay Therapeutics Inc as WATCH (do not buy) with an investment score of 43/100. Positive clinical pipeline advancement is balanced by persistent operating losses (-$302.74M in 2025) and heavy insider selling. This is algorithmic model output, not personal investment advice.
Is RLAY stock a buy?
The TradeMates model verdict for RLAY is WATCH (do not buy) with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.